# Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

> **NCT03690115** · PHASE2 · COMPLETED · sponsor: **Versailles Hospital** · enrollment: 23 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Ponatinib 30 MG

## Key facts

- **NCT ID:** NCT03690115
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-02
- **Primary completion:** 2023-12-05
- **Final completion:** 2024-12-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690115, "Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03690115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*